No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine

The Lancet Infectious Diseases

Volumn 8, Issue 5, 2008, Pages 275-276

  Ladhani, Shamez ^a   Ramsay, Mary E ^a   Chandra, Manosree ^a   Slack, Mary P ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

DRUG CONJUGATION; EUROPE; HAEMOPHILUS INFLUENZAE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LETTER; PRIORITY JOURNAL; SEROTYPE;

CAPSULES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; POLYSACCHARIDES, BACTERIAL; SEROTYPING;

EID: 42949093187     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70078-1     Document Type: Letter

References (14)

1. Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 7 (2007) 569-570
2. Heath P., and Ramsay M. Haemophilus influenzae type b vaccine-booster campaign. BMJ 326 (2003) 1158-1159
3. Rijkers G., Vermeer-de Bondt P., Spanjaard L., Breukels M., and Sanders E. Return of Haemophilus influenzae type b infections. Lancet 361 (2003) 1563-1564
4. CDC. Progress toward elimination of Haemophilus influenzae type b disease among infants and children-United States, 1987-1995. MMWR Morb Mortal Wkly Rep 45 (1996) 901-906
5. CDC. Haemophilus influenzae invasive disease among children aged <5 years-California, 1990-1996. MMWR Morb Mortal Wkly Rep 47 (1998) 737-740
6. Singleton R., Hammitt L., Hennessy T., et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 118 (2006) e421-e429
7. Heath P., Booy R., Azzopardi H., et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 284 (2000) 2334-2340
8. Takala A., Eskola J., Leinonen M., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with a Hib conjugate vaccine. J Infect Dis 164 (1991) 982-986
9. Barbour M., Mayon-White R., Coles C., Crook D., and Moxon E. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 171 (1995) 93-98
10. Forleo-Neto E., de Oliveira C., Maluf E., et al. Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis 180 (1999) 1153-1158
11. Ribeiro G., Reis J., Cordeiro S., et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 187 (2003) 109-116
12. Bajanca P., and Canica M. Emergence of non-encapsulated and encapsulated non-b-type invasive Haemophilus influenzae isolates in Portugal (1989-2001). J Clin Microbiol 42 (2004) 807-810
13. Ribeiro G., Lima J., Reis J., et al. Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil. Vaccine 5 (2007) 4420-4428
14. WHO. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81 (2006) 445-452